Goldman Sachs Upgrades Arcus Biosciences to Buy on Strong Cancer Drug Data
Goldman Sachs upgraded Arcus Biosciences to Buy, raising its price target to $28 on promising results for its lead cancer drug Casdatifan.
/ 5 items
#RCUS↓
Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival
Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.
Citi Raises Arcus Biosciences Price Target to $54 on Promising Cancer Drug Data
Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.
Arcus Biosciences’ Casdatifan Drug Scores a 'Home Run'!
Casdatifan data is a "home run"! Survival without disease worsening hit 12 months, which is double the competitor's time.